1. Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus
infection as a risk factor for squamous-cell carcinoma of the head
and neck. N Engl J Med 344:1125–1131
2. Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human
papillomavirus and rising oropharyngeal cancer incidence in the
United States. J Clin Oncol 29:4294–4301
3. Senkomago V, Henley SJ, Thomas CC et al (2019) Human
papillomavirus-attributable cancers - united states, 2012–2016.
MMWR Morb Mortal Wkly Rep 68:724–728
4. Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk
factor profiles for human papillomavirus type 16-positive and
human papillomavirus type 16-negative head and neck cancers.
J Natl Cancer Inst 100:407–420
5. Craig SG, Anderson LA, Schache AG et al (2019) Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br J
Cancer 120:827–833
6. Van Dyne EA, Henley SJ, Saraiya M et al (2018) Trends in
human papillomavirus-associated cancers - united states, 1999–
2015. MMWR Morb Mortal Wkly Rep 67:918–924
7. Mineta H, Ogino T, Amano HM et al (1998) Human papilloma
virus (HPV) type 16 and 18 detected in head and neck squamous
cell carcinoma. Anticancer Res 18:4765–4768
8. Hama T, Tokumaru Y, Fujii M et al (2014) Prevalence of human
papillomavirus in oropharyngeal cancer: a multicenter study in
Japan. Oncology 87:173–182
9. Deng Z, Hasegawa M, Matayoshi S et al (2011) Prevalence
and clinical features of human papillomavirus in head and neck
squamous cell carcinoma in Okinawa, southern Japan. Eur Arch
Otorhinolaryngol 268:1625–1631
10. Jun HW, Ji YB, Song CM et al (2021) Positive rate of human
papillomavirus and its trend in head and neck cancer in South
Korea. Front Surg 8:833048
11. Cheng D, Rao Y, Qiu J et al (2022) survival outcomes related to
treatment modalities in patients with oropharyngeal squamous
cell carcinoma. Ear Nose Throat J. DO I:1455613221115608
12. D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control
study of human papillomavirus and oropharyngeal cancer. N
Engl J Med 356:1944–1956
13. Blumberg J, Monjane L, Prasad M et al (2015) Investigation
of the presence of HPV related oropharyngeal and oral tongue
squamous cell carcinoma in Mozambique. Cancer Epidemiol
39:1000–1005
14. Drake VE, Fakhry C, Windon MJ et al (2021) Timing, number,
and type of sexual partners associated with risk of oropharyngeal
cancer. Cancer 127:1029–1038
15. Ferris RL, Westra W (2023) Oropharyngeal carcinoma with a
special focus on hpv-related squamous cell carcinoma. Annu Rev
Pathol 18:515–535
16. Roberts JN, Buck CB, Thompson CD et al (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9
and inhibited by carrageenan. Nat Med 13:857–861
17. Sano D, Oridate N (2016) The molecular mechanism of human
papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol 21:819–826
18. McIlwain WR, Sood AJ, Nguyen SA et al (2014) Initial symptoms
in patients with HPV-positive and HPV-negative oropharyngeal
cancer. JAMA Otolaryngol Head Neck Surg 140:441–447
13
980
19. Lewis JS (2017) Morphologic diversity in human papillomavirusrelated oropharyngeal squamous cell carcinoma: catch me if you
can! Mod Pathol 30:S44–S53
20. Yasui T, Morii E, Yamamoto Y et al (2014) Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer
of unknown primary origin. PLoS ONE 9:e95364
21. Tham T, Ahn S, Frank D et al (2020) Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: national
cancer database study. Head Neck 42:434–445
22. O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer
by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet
Oncol 17:440–451
23. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus
and survival of patients with oropharyngeal cancer. N Engl J Med
363:24–35
24. Shinomiya H, Kubo M, Saito Y et al (2017) Prognostic value of
ALDH2 polymorphism for patients with oropharyngeal cancer in
a Japanese population. PLoS ONE 12:e0187992
25. Saito Y, Yoshida M, Ushiku T et al (2013) Prognostic value of
p16 expression and alcohol consumption in Japanese patients with
oropharyngeal squamous cell carcinoma. Cancer 119:2005–2011
26. Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and
human papillomavirus in oropharynx cancer in TAX 324: a
subset analysis from an international phase III trial. Ann Oncol
22:1071–1077
27. Schache AG, Liloglou T, Risk JM et al (2011) Evaluation of
human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17:6262–6271
28. Weinstein GS, O’Malley BW, Snyder W et al (2007) Transoral
robotic surgery: radical tonsillectomy. Arch Otolaryngol Head
Neck Surg 133:1220–1226
29. Cracchiolo JR, Baxi SS, Morris LG et al (2016) Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous
cell carcinoma and rates of adverse pathologic features: national
cancer data base. Cancer 122:1523–1532
30. de Almeida JR, Li R, Magnuson JS et al (2015) Oncologic outcomes after transoral robotic surgery: a multi-institutional study.
JAMA Otolaryngol Head Neck Surg 141:1043–1051
31. Sinha P, Haughey BH, Kallogjeri D et al (2019) Long-term analysis of transorally resected p16 + oropharynx cancer: outcomes and
prognostic factors. Laryngoscope 129:1141–1149
32. Sethia R, Yumusakhuylu AC, Ozbay I et al (2018) Quality of life
outcomes of transoral robotic surgery with or without adjuvant
therapy for oropharyngeal cancer. Laryngoscope 128:403–411
33. Nichols AC, Theurer J, Prisman E et al (2022) Randomized trial
of radiotherapy versus transoral robotic surgery for oropharyngeal
squamous cell carcinoma: long-term results of the ORATOR trial.
J Clin Oncol 40:866–875
34. Sano D, Shimizu A, Tateya I et al (2021) Current status of transoral Surgery for patients with early-stage pharyngeal and laryngeal cancers in Japan. Front Oncol 11:804933
35. Sano D, Shimizu A, Tateya I et al (2021) Treatment outcomes of
transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma:
a multi-center retrospective observational study in Japan. Auris
Nasus Larynx 48:502–510
36. Park YM, Kim HR, Cho BC et al (2017) Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal
squamous cell carcinoma. Oral Oncol 75:16–21
37. Mensour EA, Alam S, Mawani S et al (2022) What is the future of
treatment de-escalation for HPV-positive oropharyngeal cancer?
A review of ongoing clinical trials. Front Oncol 12:1067321
13
International Journal of Clinical Oncology (2023) 28:975–981
38. Gillison ML, Trotti AM, Harris J et al (2019) Radiotherapy plus
cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised,
multicentre, non-inferiority trial. Lancet 393:40–50
39. Mehanna H, Robinson M, Hartley A et al (2019) Radiotherapy
plus cisplatin or cetuximab in low-risk human papillomaviruspositive oropharyngeal cancer (De-ESCALaTE HPV): an openlabel randomised controlled phase 3 trial. Lancet 393:51–60
40. Yom SS, Torres-Saavedra P, Caudell JJ et al (2021) Reduced-dose
radiation therapy for hpv-associated oropharyngeal carcinoma
(NRG oncology HN002). J Clin Oncol 39:956–965
41. Robert L. Ferris YF, Gregory S. Weinstein, Shuli Li, Harry Quon,
Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L.
Gillison, Umamaheswar Duvvuri, Bert W. O'malley, Enver Ozer,
Giovana R. Thomas, Wayne Koch, Michael Elliot Kupferman,
Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo
Mendez, Barbara Burtness: Transoral robotic surgical resection
followed by randomization to low- or standard-dose IMRT in
resectable p16+ locally advanced oropharynx cancer: A trial of
the ECOG-ACRIN Cancer Research Group (E3311), 2020
42. Yang MQ, Liu YC, Sui JD et al (2022) Reduced-dose radiation in
human papillomavirus-associated oropharyngeal carcinoma can
improve outcome: a systematic review and meta-analysis. Ann
Transl Med 10:1391
43. Lei J, Ploner A, Elfström KM et al (2020) HPV vaccination and
the risk of invasive cervical cancer. N Engl J Med 383:1340–1348
44. Ogilvie GS, Naus M, Money DM et al (2015) Reduction in cervical intraepithelial neoplasia in young women in British Columbia
after introduction of the HPV vaccine: an ecological analysis. Int
J Cancer 137:1931–1937
45. Palmer T, Wallace L, Pollock KG et al (2019) Prevalence of cervical disease at age 20 after immunisation with bivalent HPV
vaccine at age 12–13 in Scotland: retrospective population study.
BMJ 365:l1161
46. Shiko Y, Konno R, Konishi H et al (2020) Effectiveness of HPV
vaccination against the development of high-grade cervical lesions
in young Japanese women. BMC Infect Dis 20:808
47. Sekine M, Yamaguchi M, Kudo R et al (2021) Suspension of
proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women:
real-world data. Lancet Reg Health West Pac 16:100300
48. Cho H, Kishikawa T, Tokita Y et al (2020) Prevalence of human
papillomavirus in oral gargles and tonsillar washings. Oral Oncol
105:104669
49. Berenson AB, Hirth JM, Chang M (2022) Prevalence of oral
human papillomavirus infection: impact of sex, race/ethnicity,
and vaccination status. Clin Infect Dis 74:1230–1236
50. Yamashita Y, Ikegami T, Hirakawa H et al (2019) Staging and
prognosis of oropharyngeal carcinoma according to the 8th edition of the american joint committee on cancer staging manual
in human papillomavirus infection. Eur Arch Otorhinolaryngol.
https://doi.org/10.1007/s00405-018-05263-x
51. Maruyama H, Yasui T, Ishikawa-Fujiwara T et al (2014) Human
papillomavirus and p53 mutations in head and neck squamous cell
carcinoma among Japanese population. Cancer Sci 105:409–417
52. HPV vaccination uptake | National Cancer Control Indicators
(canceraustralia.gov.au),
53. Damgacioglu H, Sonawane K, Chhatwal J et al (2022) Longterm impact of HPV vaccination and COVID-19 pandemic on
oropharyngeal cancer incidence and burden among men in the
USA: a modeling study. Lancet Reg Health Am 8:100143
54. Brisson M, Kim JJ, Canfell K et al (2020) Impact of HPV vaccination and cervical screening on cervical cancer elimination:
a comparative modelling analysis in 78 low-income and lowermiddle-income countries. Lancet 395:575–590
International Journal of Clinical Oncology (2023) 28:975–981 981
Publisher's Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
13
...
論文の公開元へ
